Abstract
Background Despite the high number of individuals infected by SARS-CoV-2 who develop COVID-19 symptoms worldwide, many exposed individuals remain asymptomatic and/or stay uninfected. This could be explained by a combination of environmental (exposure, previous infection), epigenetic, and genetic factors. Aiming to identify genetic variants involved in SARS-CoV-2 resistance, we analyzed 86 discordant Brazilian couples where one was infected and symptomatic while the partner remained asymptomatic and seronegative despite sharing the same bedroom during the infection. The discordant partners had comparable ages, and genetic ancestry proportions.
Methods Whole-exome sequencing followed by a state-of-the-art method to call genotypes and haplotypes across the highly polymorphic MHC and LRC.
Results We observed a minor impact in antigen-presentation genes and KIR genes associated with resistance. Interestingly, genes related to immune modulation, mainly involved in NK cell killing activation/inhibition harbor variants potentially contributing to infection resistance. We hypothesize that individuals prone to produce higher amounts of MICA (possibly soluble), LILRB1, LILRB2, and low amounts of MICB, would be more susceptible to infection.
Conclusion According to this hypothesis, quantitative differences in these NK activity-related molecules could contribute to resistance to COVID-19 down regulating NK cell cytotoxic activity in infected individuals but not in resistant partners.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
This is a retrospective study on the SARS-CoV-2 infection (COVID-19) in discordant couples
Funding Statement
This work was supported by the Sao Paulo Research Foundation (FAPESP/Brazil) [grant numbers 2013/08028-1, 2014/50931-3, 2019/19998-8, and 2020/09702-1], the National Council for Scientific and Technological Development (CNPq) [grant numbers and 465355/2014-5] and JBS S.A [grant number 69004]. FAPESP/Brazil (Grants #2013/17084-0 and #2017/19223-0), and the United States National Institutes of Health - NIH (R01 GM075091) supported the development of the HLA and KIR pipeline and the genetic ancestry approach. This study was also supported by the Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior - Brasil (CAPES) - Finance Code 001, and Fleury Group (Project NP-565).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was approved by the Committee for Ethics in Research of the Institute of Biosciences at the University of Sao Paulo (CAAE 34786620.2.0000.5464). The informed consent term was obtained from all participants.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Individual level data can be shared by authors upon reasonable request.
